[tag=NNS] □
[tag=NNS] [□]
[tag=NNS] □+
Prouds - - Collections care , and the growing idea of taking a collective approach to collections care and storage ; museum collaborations ; the more central role that culture plays in economic group and tourism ; closer contact with policy - and decision-makers . " Humeston is suing Merck & Co Inc ., the maker of Vioxx , alleging the drug caused his heart attack and ultimately lowered his quality of life.Humeston 's attorney , Chris Seeger , further alleges the drug maker ignored health risks associated with its billion-dollar moneymaker and chose to put profits above patient safety . We need collaborative workshops for professional development and to raise morale.Endowment support for collections care is exciting.We should become more media savvy , in part so we can move from being just a site for education to a destination , explained Steven Rothman , collector and businessman.Paul Steinke , executive director of the University City District , noted that several institutions at the meeting - - Fort Mifflin , The Atwater Kent Museum , Eastern State Penitentiary - - had done something interesting to " reinvent " themselves in the past five years.There are an infinite number of things that the attending institutions can do to move forward , but finite resources . Capote convinced his editors at The New Yorker to let him cover the story , and set off for Kansas . His lawyer was to give his summation to the jury Tuesday , after which jurors will begin deliberations.The closing arguments capped a seven-week trial focusing on the troubled painkiller and its alleged role in Humeston 's heart attack.Its outcome has high stakes for Merck , which lost the first product liability trial over Vioxx and could face tens of thousands more lawsuits.Speaking in a hushed courtroom packed with plaintiff 's lawyers , Wall Street analysts and reporters , Sullivan led off by showing jurors a slide presentation noting the conclusions of the U.S. Food and Drug Administration , which said earlier this year that Vioxx and other so-called Cox-2 inhibitors have no risks of heart attack and stroke in short-term use .